Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Algernon’s business model is based on drug re-purposing, finding new uses for know drugs





 

Bullboard - Investor Discussion Forum Algernon Pharmaceuticals Inc C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

CSE:AGN - Post Discussion

Algernon Pharmaceuticals Inc > AGN on Market One Minute
View:
Post by StockHawk1 on Jan 06, 2023 7:18pm

AGN on Market One Minute

Algernon Pharmaceuticals (AGN.c AGNPF) was featured in Market One Minute, for being the first company to investigate DMT as a treatment for stroke. 


Their discussion went over:

- The current lack of treatment for stroke

- Stroke treatment market expected to be $15B by 2029

- AGN's belief that DMT can help the brain create new neural pathways around the damaged tissue after a stroke

- Preclinical study which shows that DMT increases neural plasticity at a sub-psychedelic dose

- Could start a trial with actual stroke patients as early as next year

- & More

 
Be the first to comment on this post
Algernon Pharmaceuticals Inc
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

Connect with C.AGN


PIPELINE TARGETED DISEASES MEDIA MANAGEMENT

CEO Clips: DMT Clinical Trial

CEO Q&A Interview with Chris Moreau

Investor Presentation

Download the latest Investor Presentaion

Algernon Highlights: The Watchlist

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Investment Opportunity

The Algernon Value Proposition



  • Advancing new drug treatments for billion dollar global disease markets.
  • Re-purposed compounds have a much lower risk of failing in human trials as a result of safety issues.
  • Conducting multiple phase II clinical trials.
  • Highly capital efficient business model.
  • Experienced management team & globally recognized medical advisory board.

Facebook

Contact Us